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A total of 10 desmoplastic small round-cell tumour patients were treated by high-dose chemotherapy with stem cell support. After
high-dose chemotherapy, no complete response conversion was obtained and EWS-WT1 fusion transcript detection was positive in
the peripheral blood during follow-up in all patients. High-dose chemotherapy did not seem to change the results in desmoplastic
small round-cell tumour.
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Desmoplastic small round-cell tumour (DSRCT) is a rare and
aggressive disease affecting mainly young male patients. Large
masses in the abdomen with compressive symptoms are frequently
observed. Morphological, immunohistochemical, and cytological
characteristics have been previously described (Gerald et al, 1998).
A recurrent chromosomal translocation t(11;22)(p13;q12) has been
found in tumour cells with detection of a chimeric transcript EWS-
WT1 using PCR.
Treatment of DSRCT is a challenge because radical surgery is
infrequently performed, and conventional chemotherapy induces
short-lived responses (Farhat et al, 1996).
Recently, the Memorial Sloan-Kettering Cancer Center group
reported interesting results using an intensive alkylator-based
protocol associated to surgery and radiotherapy (Kushner et al,
1996).
Previously, we reported the results of high-dose chemotherapy
in patients with small round-cell tumour (Bertuzzi et al, 2002).
Seven out of 28 of them were affected by DSRCT.
Here, we report the clinical and molecular results obtained in 10
adult DSRCT prospectively treated by high-dose chemotherapy
and autologous peripheral stem cell transplantation.
PATIENTS AND METHODS
Eligibility criteria
Patients with DSRCT aged 15–60 years were considered eligible for
the study. Disease staging was determined using chest X-rays,
technetium 99m bone scan, computed tomography or magnetic
resonance imaging, and the evaluation of bone marrow specimens.
The diagnosis was established on the basis of histochemical
findings as previously described (Gerald et al, 1998).
Informed consent for the treatment was obtained in accordance
with our Institutional Review-Board guidelines.
Treatment protocol
The treatment programme combined conventional chemotherapy,
local treatment (surgery and/or radiotherapy), and myeloablative
therapy with autologous stem-cell rescue. The chemotherapeutic
programme consisted of a four-course induction phase with
epirubicin 30mgm
 2, days 1–3; ifosfamide 3gm
 2, days 1–3; and
vincristine 2mg, day 1 (IVE), every 3 weeks, followed by a
mobilisation phase with high-dose etoposide (2.4gm
 2)o r
cyclophosphamide (7gm
 2), with G-CSF support. Peripheral-
blood stem cells were collected using a Cobe Spectra CS 3000.
Finally, patients in complete (CR) or partial response (PR)
received high-dose chemotherapy with melphalan 160mgm
 2
plus mitoxantrone 60mgm
 2 or thio-tepa 600mgm
 2, followed by
the reinfusion of the peripheral-blood stem cells. G-CSF
(300mgday
 1) starting on day þ5 was administered when the
number of reinfused CD34þ cells was less than 5 10
6kg
 1.
Local surgery or radiotherapy was performed, when possible,
before or after high-dose chemotherapy, on the basis of the
investigators’ best judgement.
Response evaluation
Tumour response was evaluated after four IVE courses, before the
myeloablative regimen and at the end of all therapies. Complete
remission (CR) was defined as the absence of any detectable
tumour; pertial remission (PR) was defined as a reduction in all
measurable tumours by more than 50%; stable disease (SD) was
defined as no tumour growth, in the absence of new lesions and Received 7 March 2003; accepted 18 July 2003
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lreduction in any measurable tumour by less than 50%; progressive
disease (PD) was defined as tumour growth by more than 25% in
volume or the appearance of any new lesions.
The side effects were graded using the toxicity criteria of the
National Cancer Institute.
Molecular study
Molecular analyses were made on peripheral blood and bone
marrow at the time of diagnosis, on peripheral blood alone after
the induction phase, on the leukapheresis products, and during
follow-up.
Sample preparation and RNA extraction
RNA was extracted from the peripheral-blood and bone marrow
samples, and isolated by TRIzol reagent (Gibco BRL) according to
manufacturer’s directions, and resuspended in DEPC-treated
water.
RT–PCR
A measure of 1mg of total RNA was reverse-transcribed using
200U of Maloney murine leukaemia virus RT (SuperScript II,
Gibco BRL), in a 50-ml reaction volume containing 20mM Tris-HCl,
50mM KCl pH 8.3, 0.5mM dNTPs, 10mM DTT, and 300ng of
random primers. Templates and random hexamers were first
incubated at 651C for 10min, and reverse transcription was
performed at 421C for 900; the procedure was stopped by enzyme
inactivation at 701C for 100.
Templates were amplified in standard conditions by a single
reaction in the presence of 10pmol of both WT.1 (50-GCC ACC
GAC AGC TGA AGG GC-30-30) and EWS22.3 (50-TCC TAC AGC
CAA GCT CCA AGT C-30) primers in the following cycling
conditions: 941C for 100, 35 cycles at 941C for 3000,6 5 1C for 3000,
721C for 6000, and a final extension at 721C for 100. The expected
fragment lengths vary according to the translocation type from 259
to 522bp.
All cDNAs were checked for the expression of the ubiquitously
expressed b-actin gene.
Statistical methods
Survival analysis was determined using the Kaplan–Meier
product-limit method, by computing the number of days elapsing
between the date of the start of treatment and either the date of
death or last contact for overall survival or progression for
progression-free survival. The differences between the curves were
evaluated using the log-rank test.
RESULTS
Patient characteristics and results
In all, 10 consecutive patients were treated from 1997 to 2002. All
patients were male and the median age was 29 years. Locally
advanced disease was diagnosed in six patients, while four patients
had metastatic disease.
After induction chemotherapy, five out of 10 patients (50%)
achieved a PR, two out of 10 patients (20%) had SD, and three out
of 10 patients (30%) progressed. Responsive patients received
high-dose chemotherapy, but no CR conversion was obtained.
Overall, six out of 10 patients (60%) proceeded to surgery (two
patients after and four patients before HDCT); surgery was radical
in three patients. The overall response rate after chemotherapy and
surgery was 60% (CR 30%, PR 30%), while 40% of patients showed
PD. Treatment was well tolerated and no toxic deaths were
observed.
After a median follow-up of 35 months (range 14–60), the
median overall survival was 14 months (range 7–25) (Figure 1).
EWS-WT1 fusion transcript was positive in all patients at
diagnosis in the histological samples, peripheral blood, and bone
marrow. The detection of molecular marker was always positive in
peripheral blood in all patients, when evaluated during treatment
and in leukapheresis products. Only one patient submitted to
allogeneic peripheral stem cell transplantation after a reduced-
intensity conditioning regimen showed the disappearance of
fusion transcript at the time of cyclosporine tapering and acute
graft versus host disease (GvHD) development (Figure 2).
DISCUSSION
The results of this prospective study suggest that high-dose
chemotherapy does not improve clinical results in DSRCT. Indeed,
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Figure 1 Overall survival (dotted line) and progression-free survival.





Figure 2 Molecular results in patients treated with allogeneic stem cell
transplantation with a reduced-intensity conditioning regimen.
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lpartial responders after induction chemotherapy did not
show a CR conversion with high-dose chemotherapy. Further-
more, no complete responders ever obtained clearance of
EWS-WT1 fusion transcript, during the different steps of
treatment, and the median overall survival remained dismal (14
months).
Interesting data have been previously reported in literature by
Kusher et al, using an intensive alkylator-based chemotherapy
combined with surgery and radiotherapy, with a 3-year overall
survival of 29%. The chemotherapy regimen is aggressive even
if in their original report only four (CR – two, PR – two) out
of 12 patients received high-dose chemotherapy with PSC
support and the two PRs were not converted to CR. Two main
differences were evident compared to the present series: the
higher dose of alkylator and the application of radiotherapy to the
whole abdomen. However, after the chemotherapy, response rate
(66%) was comparable to that achieved in our series (60%) and
with regard to radiotherapy (Goodman et al, 2002), mainly
hematological and intestinal toxicity (bowel obstruction in 33%),
is considerable, and radiotherapy does not seem to modify the
overall results.
Considering the presence of a recurrent translocation with a new
hybrid transcript with antigenic proprieties in DSRCT (Worley
et al, 2001), we treated a patient progressing after chemotherapy
and surgery with matched sibling allograft using a reduced-
intensity conditioning regimen. The patient rapidly obtained a full
donor chimerism and cyclosporine was tapered when tumour
progression was documented. He developed acute GvHD (grade
III) and extensive chronic GvHD. Molecular monitoring of the
presence of hybrid transcript in peripheral blood, previously
positive, was converted to negative after GvHD development
(Figure 2). This phenomenon could be interpreted as a graft versus
desmoplastic effect.
In conclusion, high-dose chemotherapy does not change the fate
of DSRCT. Considering the low incidence of this tumour,
cooperative studies should be planned. Furthermore, allogeneic
stem cell transplantation should be more extensively explored in
these young patients.
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